On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
